Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)	Neoplasms by Site, Thoracic Neoplasms, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm	Recruiting	Phase 2	2026-04-30		NCT04591002

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Samsung Medical Center	207

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Samsung Medical Center	Seoul	South Korea	170
SMC	Seoul	South Korea	1

Clinical trials